Forbion, Seroba co-lead €29m series-B for Prexton

The company's existing investors, Merck Ventures, Ysios Capital and Sunstone Capital, also participated in the funding round. As part of the deal, Forbion's partner Marco Boorsma and Seroba's partner Alan O'Connell will join the company's board.

According to a statement, the company plans on using the capital injection to boost phase II of efficacy trials for its Parkinson's-focused therapy. Moreover, the GP will boost the company's expansion in the Netherlands where it will start its trial phase.

Company
Founded in 2012 and based in Geneva, Prexton is a biopharmaceutical business that develops a treatment named Foliglurax, which integrates molecular, behavioural and chemistry technologies to address Parkinson's disease and other brain disorders.

People
Forbion Capital Partners – Marco Boorsma (partner).
Seroba Life Sciences – Alan O'Connell (partner).
Prexton Therapeutics – Francois Conquet (founder, CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Healthcare
• DACH
• Venture
• Switzerland